Expanding the Scope of Base Editing

扩大碱基编辑的范围

基本信息

  • 批准号:
    9768957
  • 负责人:
  • 金额:
    $ 42.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-23 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary: Expanding the Scope of Base Editing Genome editing has revolutionized the life sciences and offers the potential to cure genetic diseases. We recently developed base editing, a method of making single-base changes at target genomic sites without introducing double-strand breaks or relying on homologous recombination. Base editors (BEs) are especially relevant for the study and treatment of genetic diseases because the majority of disease-relevant mutations are single-base changes. In the two years since we pioneered base editing with a C•G-to-T•A editor, we have improved BE efficiency and product purity, reduced off-target and bystander base editing, evolved a new class of adenine base editors (ABEs) that convert A•T to G•C base pairs, expanded the targeting scope of BEs, established base editing of post-mitotic somatic cells in vivo, and applied BEs to record cellular events. Hundreds of other laboratories around the world have used base editing to study genetic diseases and to test potential therapeutic strategies. Here we propose to expand the capabilities of base editors towards the transformative goal of enabling any desired base change at any target locus in any somatic cell. Base editing requires the presence of an appropriately positioned protospacer adjacent motif (PAM) for binding of the Cas9 domain. Most DNA sites remain inaccessible for genome editing due to the lack of any DNA-binding CRISPR protein that recognizes the majority of PAMs. To further expand our ability to base edit the broadest range of targets, we will use our phage-assisted continuous evolution (PACE) platform to rapidly evolve a collection of Cas9 variants that recognize currently many untargetable PAM sequences (Aim 1a). The targeting scope of BEs is also limited by inefficient editing of certain base pairs because of sequence context. To further expand the targeting scope of base editing, we will use our recently established PACE selection for base editing to generate BEs that can efficiently modify targets with currently disfavored flanking sequences (Aim 1b). Base editors modify bases within the editing window, a range of ~5 nucleotides positioned relative to the PAM. In addition to conversion of the target C•G or A•T base pair, other “bystander” C•G or A•T base pairs are also edited within this window. These bystander edits can lead to undesired genome changes. To minimize bystander base editing, we propose to evolve a large set of BEs that will only edit bases within specific sequence contexts (Aim 2), thereby enabling discrimination between multiple Cs or As within the editing window. Finally, a major limitation of base editing is the inability to generate transversion (purine ßà pyrimidine) mutations, which are needed to install or correct ~38% of known human pathogenic SNPs. We propose to develop the first base editors that can generate transversion mutations at target base pairs using two distinct strategies (Aims 3a and 3b). Success with either strategy would greatly expand the capabilities of base editing, and would also allow, in principle, all 12 possible base-to-base change via individual or sequential use of transition and transversion editors.
项目总结:扩大碱基编辑的范围

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID R LIU其他文献

DAVID R LIU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID R LIU', 18)}}的其他基金

Project 3: Therapeutic Gene Editing for Huntington's Disease
项目3:亨廷顿病的治疗性基因编辑
  • 批准号:
    10668769
  • 财政年份:
    2023
  • 资助金额:
    $ 42.21万
  • 项目类别:
Gene Editing Core
基因编辑核心
  • 批准号:
    10668765
  • 财政年份:
    2023
  • 资助金额:
    $ 42.21万
  • 项目类别:
Project 2: Therapeutic Gene Editing for Friedreich's Ataxia
项目 2:弗里德赖希共济失调的治疗性基因编辑
  • 批准号:
    10668768
  • 财政年份:
    2023
  • 资助金额:
    $ 42.21万
  • 项目类别:
Base editing and prime editing for sickle cell disease
镰状细胞病的碱基编辑和引物编辑
  • 批准号:
    10157511
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
Continuous Evolution of Proteins with Novel Therapeutic Potential
具有新治疗潜力的蛋白质的不断进化
  • 批准号:
    10181559
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
Base editing and prime editing for sickle cell disease
镰状细胞病的碱基编辑和引物编辑
  • 批准号:
    10323054
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
Base editing and prime editing for sickle cell disease
镰状细胞病的碱基编辑和引物编辑
  • 批准号:
    10579903
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
Continuous Evolution of Proteins with Novel Therapeutic Potential
具有新治疗潜力的蛋白质的不断进化
  • 批准号:
    10588186
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
Continuous Evolution of Proteins with Novel Therapeutic Potential
具有新治疗潜力的蛋白质的不断进化
  • 批准号:
    10393666
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
PedGeneRx - Admin Supplement to Base Editing and Prime Editing for Sickle Cell Disease R01
PedGeneRx - 镰状细胞病 R01 碱基编辑和 Prime 编辑的管理补充
  • 批准号:
    10594247
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:

相似海外基金

The Role of Adenine Nucleotide Translocase in Mitochondrial Dysfunction Associated Senescence in Chronic Obstructive Pulmonary Disease (COPD)
腺嘌呤核苷酸转位酶在慢性阻塞性肺病(COPD)线粒体功能相关衰老中的作用
  • 批准号:
    10633608
  • 财政年份:
    2023
  • 资助金额:
    $ 42.21万
  • 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
  • 批准号:
    10794933
  • 财政年份:
    2022
  • 资助金额:
    $ 42.21万
  • 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
  • 批准号:
    10534031
  • 财政年份:
    2022
  • 资助金额:
    $ 42.21万
  • 项目类别:
Development of nobel assay methods for miRNA and adenine methyltransferase using FRET
使用 FRET 开发 miRNA 和腺嘌呤甲基转移酶的诺贝尔检测方法
  • 批准号:
    21K05120
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Critical assessment of DNA adenine methylation in brain cells from healthy aging and Alzheimer's disease
健康老龄化和阿尔茨海默病脑细胞 DNA 腺嘌呤甲基化的批判性评估
  • 批准号:
    10365337
  • 财政年份:
    2021
  • 资助金额:
    $ 42.21万
  • 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
  • 批准号:
    10033546
  • 财政年份:
    2020
  • 资助金额:
    $ 42.21万
  • 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
  • 批准号:
    10613902
  • 财政年份:
    2020
  • 资助金额:
    $ 42.21万
  • 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
  • 批准号:
    10226235
  • 财政年份:
    2020
  • 资助金额:
    $ 42.21万
  • 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
  • 批准号:
    10396102
  • 财政年份:
    2020
  • 资助金额:
    $ 42.21万
  • 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
  • 批准号:
    10705982
  • 财政年份:
    2020
  • 资助金额:
    $ 42.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了